Tezosentan in the management of decompensated heart failure

Cardiology in Review

Volumn 13, Issue 1, 2005, Pages 28-34

  Cheng, Judy W M ^a,b  

^a LONG ISLAND UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelin receptor blockers; Heart failure; Tezosentan

Indexed keywords

BOSENTAN; CYCLOSPORIN; DIURETIC AGENT; DOBUTAMINE; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; LIVER ENZYME; MILRINONE; NEUROHORMONE; NITROPRUSSIDE SODIUM; TEZOSENTAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; BACKACHE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CRANIOFACIAL MALFORMATION; DATA BASE; DISEASE EXACERBATION; DIZZINESS; DRUG BILE LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; ECONOMIC ASPECT; ENZYME BLOOD LEVEL; FETUS MALFORMATION; FLUSHING; HEADACHE; HEALTH CARE MANAGEMENT; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPOTENSION; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MEDIATOR; MEDICAL LITERATURE; MUSCLE CRAMP; NAUSEA; PAIN; PATHOPHYSIOLOGY; PATIENT; REVIEW; SIDE EFFECT; STEADY STATE; THORAX PAIN; TIME; TREATMENT CONTRAINDICATION; VOMITING;

DRUG TOLERANCE; HEADACHE; HEART FAILURE, CONGESTIVE; HUMANS; HYPOTENSION; PYRIDINES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ENDOTHELIN; TETRAZOLES; TREATMENT OUTCOME;

EID: 13444263634     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000137737.54951.aa     Document Type: Review

References (34)

1. 2003 Heart and stroke statistical update. Dallas: American Heart Association; 2003.
2. Burger MR, Burger AJ. BNP in decompensated heart failure: diagnostic, prognostic and therapeutic potential. Curr Opin Investig Drugs. 2001;2:929-935.
3. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine and hemodynamic effects of brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76:91-96.
4. Levin E. Endothelins. N Engl J Med. 1995;333:356-363.
5. Parker JD, Thiessen JJ, Reilly R, et al. Human endothelin-1 clearance kinetics revealed by a radiotracer technique. J Pharmacol Exp Ther. 1999;289:261-265.
6. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
7. Ellahham SH, Charlon V, Abassi Z, et al. Bosentan and the endothelin system in congestive heart failure. Clin Cardiol. 2000;23:803-807.
8. Battistini B, Chauler P, DOrleans-Juste P, et al. Growth regulatory properties of endothelins. Peptides. 1993;14:385-399.
9. Kaddoura S, Firth JD, Boheler KR, et al. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Circulation. 1996;93:2068-2079.
10. Muller DN, Mervaala EM, Schmidt F, et al. Effect of bosentan on NF-kb, inflammation, and tissue factor in angiotensin II-induced end organ damage. Hypertension. 2000;36:282-290.
11. Mansoor AM, Honda M, Saida K, et al. Endothelin induced collagen remodeling in experimental pulmonary hypertension. Biochem Biophys Res Commun. 1995;215:981-986.
12. Piacentini L, Honda M, Saida K, et al. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol. 2000;32:565-576.
13. Peifley KA, Winkles JA. Angiotensin II and endothelin-1 increase fibroblast growth factor-2 m-RNA expression in vascular smooth muscle cells. Biochem Biophys Res Commun. 1998;242:202-208.
14. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2000;103:72-77.
15. Pacher R, Stanek B, Hulsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633-641.
16. Benigni A, Zoja C, Corna D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993;44:440-444.
17. Benigni A, Remuzzi G. Endothelin antagonists. Lancet. 1999;353:133-138.
18. Clozel M, Rumuz H, Clozel JP, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther. 1999;290:840-846.
19. Duchman SM, Thohan V, Kalra D, et al. Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure. Curr Opin Cardiol. 2000;15:136-140.
20. Dingemanse J, Clozel M, Van Giersbergen P. Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist. J Cardiovasc Pharmacol. 2002;39:795-802.
21. Dingemanse J, Clozel M, Giersbergen P. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. Br J Clin Pharmacol. 2002;53:355-362.
22. Tovar JM, Gums JG. Tezosentan in the treatment of acute heart failure. Ann Pharmacother. 2003;37:1877-1883.
23. Dingemanse J, van Giersbergen PL. Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile. Br J Clin Pharmacol. 2004;57:344-348.
24. Schalcher C, Cotter G, Reisin L, et al. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J. 2001;142:340-349.
25. Torre-Amione G, Young JB, Durand JB, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation. 2001;103:973-980.
26. Rich S, MaLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation. 2003;108:2184-2190.
27. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2003;42:140-147.
28. O'Connor CM, Gattis WA, Adams KF, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes. J Am Coll Cardiol. 2003;41:1452-1457.
29. Kaluski E, Kobrin I, Zimlichman R, et al. RITZ-5: randomized intravenous tezosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema. J Am Coll Cardiol. 2003;41:204-210.
30. Torre-Amione G, Durand JB, Nagueh S, et al. A pilot safety trial of prolonged (48 hours) infusion of the dual endothelin receptor antagonist tezosentan in patients with advanced heart failure. Chest. 2001;120:460-466.
31. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 1994;368:703-710.
32. van Giersbergen PL, Bodin F, Dingermanse J. Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist. Eur J Clin Pharmacol. 2002;58:243-245.
33. Frishman WH, Kaur S, Singh I, et al. Endothelin as a therapeutic target in the treatment of cardiovascular disease. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 2nd ed. New York: McGraw Hill; 2003:527-543.
34. Schirger JA, Chen HH, Jougasaki M, et al. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation. 2004;109:249-254.